Silimed Benelux
ActiveFrom the official registers: KBO 3 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
The computed 12-month bankruptcy probability of Silimed Benelux is 1.9% (moderate). The 2025 annual accounts show negative equity (-€809,778) and a net result of -€330,298. Equity has been shrinking by about 70% per year since 2023. Its solvency ranks better than 6% of 9,829 sector peers (NACE 46, financial year 2025). The company has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals.
Overview
Official details
KBO- Status
- Active since 01-12-2022 Normal situation
- Activity
- Wholesale of pharmaceutical and medical goods NACE 46460
- Establishment unit
- 2.338.581.611 2800 Mechelen, since 01-12-2022
- Financial year end
- 31 December
- Peppol
- Reachable since 05-12-2022
Financial position
- Bankruptcy probabilitywithin 12 months
- 1.9%
- Gross margin
- €153,033
- ▲ 343%
- Turnover
- ≈ €630,000
- estimated
- Loss
- €330,298
- ▼ 2.7%
- Equity
- -€809,778
- ▼ 68.9%
- Total assets
- €1.5m
- ▲ 33.2%
- Staff
- 3 FTE
- ▲ 7.1%
Score breakdownraises riskNegative equity -€809,778Loss of €330,298, the second in a row (financial year 2025)lowers riskFounded in 2022Size: 3 FTE, total assets €1.5mShow the evidence
Checked score
About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, micro). It does better than 6% of them on solvency, 13% on liquidity, 6% on profitability and 7% on growth.
The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 3 accounts on average 11 days before the deadline. In the sector (NACE 46), the median for financial year 2024 was 3 days before the deadline, and 39% of those companies filed late.
Searched, nothing found (2)
Key points
- Risk: Negative equitydebts exceed assets in financial year 2025 -€809,778 View
- Risk: 3 loss-making years in a rowloss in financial year 2025 -€330,298 View
- Caution: Lower net result than 95% of companies in wholesale tradesector median €26,864 · 9,808 companies -€330,298 View
- Caution: Equity fell in 2025from -€479,480 to -€809,778 ▼ 68.9% View
Comparable companies
These companies have the same main activity as Silimed Benelux: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €570,000 and €2.1m, founded between 2021 and 2023.
| Company | Total assets | Gross margin |
|---|---|---|
| Silimed Benelux Mechelen | €1.5m | €0.2m |
| LÖWENSTEIN MEDICAL BELGIUM Blégny | €1.6m | €0.1m |
| More2C Lievegem | €1.0m | €0.3m |
| Grindeks Kalceks Belgium Aalst | €2.1m | €0.4m |
| Mediso Medical Imaging Systems Belgium Oudergem | €1.3m | €0.5m |
| Pharmacie Herboristerie Marie Curie Charleroi | €0.6m | €0.3m |
| HYGEMED Mons | €0.6m | €0.2m |
Documents
Annual accounts at the NBB
- Annual accounts 2025filed on 30-07-2026
- Annual accounts 2024filed on 18-07-2025
- Annual accounts 2023filed on 12-07-2024
Acts in the Belgian Official Gazette
- Resignations & appointmentsact of 13-09-2023
- Incorporationact of 05-12-2022
Articles and registers
- Coordinated articles of associationnotaries' database
- Entry in the KBO registerKBO Public Search
Key facts about Silimed Benelux
- What is the company number of Silimed Benelux?
- The company number of Silimed Benelux is 0794.305.284. The VAT number is the same number with BE in front: BE 0794.305.284.
- Where is Silimed Benelux based?
- The registered office is at Motstraat 60K, 2800 Mechelen.Company details
- What does Silimed Benelux do?
- According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
- What is the legal form of Silimed Benelux?
- The legal form of Silimed Benelux is Private limited company (BV).
- When was Silimed Benelux founded?
- Silimed Benelux was founded on 01-12-2022.
- Is Silimed Benelux still active?
- Yes, Silimed Benelux is an active enterprise in the KBO register.
- How many employees does Silimed Benelux have?
- Silimed Benelux had an average of 3 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of Silimed Benelux?
- The turnover in financial year 2025 is ≈ €630,000. This figure is estimated from the gross margin of €153,033 and 30 comparable companies (NACE 464). It probably lies between €390,000 and €870,000.
- Is Silimed Benelux profitable?
- In financial year 2025, Silimed Benelux made a loss of €330,298.
- Where can I find the annual accounts of Silimed Benelux?
- Silimed Benelux filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts at the National Bank
- When are the next annual accounts of Silimed Benelux due?
- Silimed Benelux must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.